Sandoz Group AG
- Country
- ๐ฉ๐ชGermany
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 20K
- Market Cap
- $19B
- Website
- http://www.sandoz.com
An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002008
- Locations
- ๐บ๐ธ
UCLA CARE Ctr, Los Angeles, California, United States
๐บ๐ธBeth Israel Deaconess - West Campus, Boston, Massachusetts, United States
A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002268
- Locations
- ๐บ๐ธ
Univ of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธUniv TX Galveston Med Branch, Galveston, Texas, United States
A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002252
- Locations
- ๐บ๐ธ
USC School of Medicine, Los Angeles, California, United States
๐บ๐ธUCSD Med Ctr, San Diego, California, United States
๐บ๐ธRush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002009
- Locations
- ๐บ๐ธ
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
๐บ๐ธUCLA CARE Ctr, Los Angeles, California, United States
A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002007
- Locations
- ๐บ๐ธ
Natl Cancer Institute, Bethesda, Maryland, United States
A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002253
- Locations
- ๐บ๐ธ
USC School of Medicine, Los Angeles, California, United States
๐บ๐ธMed Service, Miami, Florida, United States
๐บ๐ธEmory Univ School of Medicine, Atlanta, Georgia, United States
A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002263
- Locations
- ๐บ๐ธ
Natl Cancer Institute / HIV / AIDS Malignancy Branch, Bethesda, Maryland, United States